Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase NA 5Phase 4 2Phase 3 2Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Sarcoma 1Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 28Leukemia, Myeloid, Acute 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia 23Lymphoma 22Small Cell Lung Carcinoma 20Burkitt Lymphoma 19Lymphoma, Non-Hodgkin 18Lung Neoplasms 13Recurrence 12Neuroblastoma 12Lymphoma, Mantle-Cell 12Leukemia, Lymphocytic, Chronic, B-Cell 12Congenital Abnormalities 12Myelodysplastic Syndromes 11Lymphoma, Follicular 11Brain Neoplasms 10Hodgkin Disease 9Carcinoma, Non-Small-Cell Lung 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myeloid, Accelerated Phase 8Leukemia, Monocytic, Acute 8Leukemia, Megakaryoblastic, Acute 8Leukemia, Erythroblastic, Acute 8Blast Crisis 8Sarcoma 7Neoplasms 7Myeloproliferative Disorders 7Multiple Myeloma 7

Interventions

Vorinostat 5Bortezomib 5fludarabine phosphate 4Doxorubicin 3Dasatinib 3Cyclophosphamide 3romidepsin 2Vincristine 2Pharmacogenomic Testing 2Oxaliplatin 2Lenalidomide 2Everolimus 2Etoposide 2Biopsy 2Bevacizumab 2Azacitidine 2vandetanib 1tirbanibulin 1temsirolimus 1tanespimycin 1siplizumab 1ontuxizumab 1obatoclax 1methoxyamine 1liposomal doxorubicin 1imetelstat 1gossypol acetic acid 1ganitumab 1fludarabine 1duvelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Extranodal NK-T-Cell × Etoposide × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT00101205 2014-02-24

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled
DermatologicLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Mycosis Fungoides, Recurrence, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡